Company intelligence / Profile preview

MyGenome

Ownership: Private
Development stage: Commercial

Overview

MyGenome offers in-house molecular genomic tests using advanced sequencing and PCR techniques. Their services include liquid biopsy-based risk assessment for various disease categories, with recent expansion into microbial product testing. The company is supported by experienced scientists and aims to provide affordable preventive genomic screening in Southeast Asia. No clinical trial results as they are not a drug developer.

Therapeutic areas: OncologyMetabolic DisordersRare DiseasesOtherCardiovascularNeurology
Modalities: Genomic testingNext Generation Sequencing (NGS)Digital gene platformReal-Time & Standard PCR
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on MyGenome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyGenome.

Explore the full profile